Cargando…
PROTACs are effective in addressing the platelet toxicity associated with BCL-X(L) inhibitors
BCL-X(L) is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-X(L) has also been identified as a key survival factor in senescent cells. Accumulation of senescent cells has been indicated a...
Autores principales: | Zhang, Peiyi, Zhang, Xuan, Liu, Xingui, Khan, Sajid, Zhou, Daohong, Zheng, Guangrong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293695/ https://www.ncbi.nlm.nih.gov/pubmed/34296214 http://dx.doi.org/10.37349/etat.2020.00017 |
Ejemplares similares
-
A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity
por: Khan, Sajid, et al.
Publicado: (2019) -
BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022) -
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020) -
Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x(L) Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches
por: Negi, Arvind, et al.
Publicado: (2022) -
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)